[Featured Stock] Shinil Pharmaceutical, 20 Million COVID-19 Cases in the US... Dexamethasone Supply Shortage Becomes a Reality

[Asia Economy Reporter Hyungsoo Park] Shinil Pharmaceutical, which plummeted the previous day, is making a sharp rebound. The resurgence of COVID-19 in the United States and the rising talk of a 'second lockdown' appear to be affecting the stock price.

As of 9:43 a.m. on the 26th, Shinil Pharmaceutical is trading at 14,450 won, up 11.15% from the previous day. It is rebounding after a drop of more than 16% the day before.

With the number of confirmed COVID-19 cases in the U.S. reaching 2.4 million, there is speculation that the actual number of infected people could be ten times higher. Robert Redfield, director of the Centers for Disease Control and Prevention (CDC), stated in a conference call, "COVID-19 has many asymptomatic infections," and "Our current assessment is that for every reported COVID-19 infection, there are another 10 infections." This means that the actual number of COVID-19 infections in the U.S. could reach 23 million.

As concerns about a second wave of COVID-19 grow, a shortage of the anti-inflammatory steroid drug 'Dexamethasone' continues. According to major scientific foreign media, Steven Schoendellmeyer, director of the Pharmaceutical and Economic Research Institute at the University of Minnesota, USA, pointed out, "The optimistic outlook that Dexamethasone will be easily available is too hasty and does not properly consider the data."

He said, "Following the release of positive clinical results for severe COVID-19 patients, a shortage of the drug due to hoarding has already appeared."

Shinil Pharmaceutical manufactures pills with Dexamethasone as the main ingredient.

This content was produced with the assistance of AI translation services.